{"id":"NCT01965652","sponsor":"Shionogi","briefTitle":"Long Term Safety of Naldemedine","officialTitle":"A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluate the Long-term Safety of Naldemedine for the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09-24","primaryCompletion":"2016-01-12","completion":"2016-01-12","firstPosted":"2013-10-18","resultsPosted":"2017-05-30","lastUpdate":"2018-04-18"},"enrollment":1246,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Opioid-induced Constipation"],"interventions":[{"type":"DRUG","name":"Naldemedine","otherNames":["S-297995","SymproicÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Naldemedine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the long-term safety of naldemedine for the treatment of constipation due to opioid therapy.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"From the first dose of study drug up to 14 days after the last dose of study drug (54 weeks).","effectByArm":[{"arm":"Naldemedine","deltaMin":425,"sd":null},{"arm":"Placebo","deltaMin":446,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":186,"countries":["United States","Australia","Austria","Canada","Czechia","Denmark","France","Germany","Hungary","Israel","Italy","Poland","South Africa","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["34295186","32280263","32086791"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":60,"n":621},"commonTop":["Diarrhoea","Urinary Tract Infection","Nausea","Upper Respiratory Tract Infection","Abdominal Pain"]}}